BillionToOne is developing diagnostic tools for genetic-based disease testing. The human genome consists of three billion nucleotides each containing one of four bases, A,T, C or G. Several common and severe recessive conditions are caused by single changes in the DNA sequence. To detect and quantify diseases at single base-pair resolution, BillionToOne has created their proprietary Quantitative Counting Templates (QCTs). BillionToOne’s QCT technology can be quantified using cell-free DNA enabling disease detection to be made from liquid samples as used in prenatal screening or liquid biopsies. Using their technology, BillionToOne has commercialized a non-invasive prenatal test, UNITY Screen, to assess fetal risk for recessive conditions and is developing liquid biopsy products.

BillionToOne

Founded: 2016
Location: Menlo Park, CA
Employee range: 50 - 200
Funding: $48.5M Dec 2022; $125M C Mar 2022; $55M B Jun 2021; $15M A+ Mar 2019
Investors: Hummingbird Ventures, NeoTribe Ventures, Y Combinator

Short description:

Drug notes:

Long description:

Jobs: